Resistance outside the substrate envelope: hepatitis C NS3/4A protease inhibitors

References

• Agarwal A, Zhang B, Olek E, Robison H, Robarge L, Deshpande M. 2012. Rapid and sharp decline in HCV upon monotherapy with NS3 protease inhibitor, ACH-1625. Antivir Ther (Lond). 17:1533–1539.
   PubMed Web of Science ®Google Scholar
• Ali A, Aydin C, Gildemeister R, Romano KP, Cao H, Ozen A, Soumana D, Newton A, Petropoulos CJ, Huang W. 2013. Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance. ACS Chem Biol. 8:1469–1478.
   PubMed Web of Science ®Google Scholar
• Arasappan A, Bennett F, Bogen SL, Venkatraman S, Blackman M, Chen KX, Hendrata S, Huang Y, Huelgas RM, Nair L, et al. 2010. Discovery of narlaprevir (sch 900518): a potent, second generation HCV NS3 serine protease inhibitor. ACS Med Chem Lett. 1:64–69.
   PubMed Web of Science ®Google Scholar
• Au JS, Pockros PJ. 2014. Novel therapeutic approaches for hepatitis C. Clin Pharmacol Ther. 95:78–88.
   PubMed Web of Science ®Google Scholar
• Aydin C, Mukherjee S, Hanson AM, Frick DN, Schiffer CA. 2013. The interdomain interface in bifunctional enzyme protein 3/4A (NS3/4A) regulates protease and helicase activities. Protein Sci. 22:1786–1798.
   PubMed Web of Science ®Google Scholar
• Banks JL, Beard HS, Cao Y, Cho AE, Damm W, Farid R, Felts AK, Halgren TA, Mainz DT, Maple JR, et al. 2005. Integrated Modeling Program, Applied Chemical Theory (IMPACT). J Comput Chem. 26:1752–1780.
   PubMed Web of Science ®Google Scholar
• Bukh J, Miller RH, Purcell RH. 1995a. Biology and genetic heterogeneity of hepatitis C virus. Clin Exp Rheumatol. 13 S3–S7.
   PubMed Web of Science ®Google Scholar
• Bukh J, Miller RH, Purcell RH. 1995b. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis. 15:41–63.
   PubMed Web of Science ®Google Scholar
• Chen Z, Benureau Y, Rijnbrand R, Yi J, Wang T, Warter L, Lanford RE, Weinman SA, Lemon SM, Martin A, et al. 2007. GB virus B disrupts RIG-I signaling by NS3/4A-mediated cleavage of the adaptor protein MAVS. J Virol. 81:964–976.
   PubMed Web of Science ®Google Scholar
• Cummings MD, Lindberg J, Lin TI, de Kock H, Lenz O, Lilja E, Fellander S, Baraznenok V, Nystrom S, Nilsson M, et al. 2010. Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target. Angew Chem Int Ed Engl. 49:1652–1655.
   PubMed Web of Science ®Google Scholar
• De Clercq E. 2014. Current race in the development of DAAs (direct-acting antivirals) against HCV. Biochem Pharmacol. 89:441–452.
   PubMed Web of Science ®Google Scholar
• De Francesco R, Migliaccio G. 2005. Challenges and successes in developing new therapies for hepatitis C. Nature. 436:953–960.
   PubMed Web of Science ®Google Scholar
• GraphPad Software. 2016. GraphPad Prism for Mac OSX. Version 6.0. San Diego (CA): GraphPad Software.
   Google Scholar
• Guan Y, Sun H, Li Y, Pan P, Li D, Hou T. 2014. The competitive binding between inhibitors and substrates of HCV NS3/4A protease: a general mechanism of drug resistance. Antiviral Res. 103:60–70.
   PubMed Web of Science ®Google Scholar
• Guan Y, Sun H, Pan P, Li Y, Li D, Hou T. 2015. Exploring resistance mechanisms of HCV NS3/4A protease mutations to MK5172: insight from molecular dynamics simulations and free energy calculations. Mol Biosyst. 11:2568–2578.
   PubMed Web of Science ®Google Scholar
• Harper S, McCauley JA, Rudd MT, Ferrara M, DiFilippo M, Crescenzi B, Koch U, Petrocchi A, Holloway MK, Butcher JW, et al. 2012. Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor. ACS Med Chem Lett. 3:332–336.
   PubMed Web of Science ®Google Scholar
• He Y, King MS, Kempf DJ, Lu L, Lim HB, Krishnan P, Kati W, Middleton T, Molla A. 2008. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system. Antimicrob Agents Chemother. 52:1101–1110.
   PubMed Web of Science ®Google Scholar
• Heim MH. 2013. Innate immunity and HCV. J Hepatol. 58:564–574.
   PubMed Web of Science ®Google Scholar
• Idrees S, Ashfaq UA. 2013. HCV infection and NS-3 serine protease inhibitors. Virol Mycol. 2:112. doi:10.4172/2161-0517.1000112
   Google Scholar
• Jensen SB, Serre SB, Humes DG, Ramirez S, Li YP, Bukh J, Gottwein JM. 2015. Substitutions at NS3 residue 155, 156, or 168 of hepatitis C virus genotypes 2 to 6 induce complex patterns of protease inhibitor resistance. Antimicrob Agents Chemother. 59:7426–7436.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Andrews SW, Condroski KR, Buckman B, Serebryany V, Wenglowsky S, Kennedy AL, Madduru MR, Wang B, Lyon M, et al. 2014. Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease. J Med Chem. 57:1753–1769.
   PubMed Web of Science ®Google Scholar
• Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, Kwong AD, Zeuzem S. 2007. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology. 46:631–639.
   PubMed Web of Science ®Google Scholar
• King NM, Prabu-Jeyabalan M, Nalivaika EA, Schiffer CA. 2004. Combating susceptibility to drug resistance: lessons from HIV-1 protease. Chem Biol. 11:1333–1338.
   PubMed Web of Science ®Google Scholar
• Kurt Yilmaz N, Swanstrom R, Schiffer CA. 2016. Improving viral protease inhibitors to counter drug resistance. Trends Microbiol. 24:547–557.
   PubMed Web of Science ®Google Scholar
• Kwong AD, Kauffman RS, Hurter P, Mueller P. 2011. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat Biotechnol. 29:993–1003.
   PubMed Web of Science ®Google Scholar
• Lange CM, Sarrazin C, Zeuzem S. 2010. Review article: specifically targeted anti-viral therapy for hepatitis C – a new era in therapy. Aliment Pharmacol Ther. 32:14–28.
   PubMed Web of Science ®Google Scholar
• Lemke CT, Goudreau N, Zhao S, Hucke O, Thibeault D, Llinas-Brunet M, White PW. 2011. Combined X-ray, NMR, and kinetic analyses reveal uncommon binding characteristics of the hepatitis C virus NS3-NS4A protease inhibitor BI 201335. J Biol Chem. 286:11434–11443.
   PubMed Web of Science ®Google Scholar
• Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, Ray SC, Gale M, Jr., Lemon SM. 2005. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA. 102:2992–2997.
   PubMed Web of Science ®Google Scholar
• Lin C, Gates CA, Rao BG, Brennan DL, Fulghum JR, Luong YP, Frantz JD, Lin K, Ma S, Wei YY, et al. 2005. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem. 280:36784–36791.
   PubMed Web of Science ®Google Scholar
• Lin C, Kwong AD, Perni RB. 2006. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets. 6:3–16.
   PubMedGoogle Scholar
• Lin TI, Lenz O, Fanning G, Verbinnen T, Delouvroy F, Scholliers A, Vermeiren K, Rosenquist A, Edlund M, Samuelsson B, et al. 2009. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother. 53:1377–1385.
   PubMed Web of Science ®Google Scholar
• Liverton NJ, Carroll SS, Dimuzio J, Fandozzi C, Graham DJ, Hazuda D, Holloway MK, Ludmerer SW, McCauley JA, McIntyre CJ, et al. 2010. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob Agents Chemother. 54:305–311.
   PubMed Web of Science ®Google Scholar
• Llinas-Brunet M, Bailey M, Fazal G, Goulet S, Halmos T, Laplante S, Maurice R, Poirier M, Poupart MA, Thibeault D, et al. 1998. Peptide-based inhibitors of the hepatitis C virus serine protease. Bioorg Med Chem Lett. 8:1713–1718.
   PubMed Web of Science ®Google Scholar
• Llinas-Brunet M, Bailey MD, Goudreau N, Bhardwaj PK, Bordeleau J, Bos M, Bousquet Y, Cordingley MG, Duan J, Forgione P, et al. 2010. Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335). J Med Chem. 53:6466–6476.
   PubMed Web of Science ®Google Scholar
• Lontok E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, McPhee F, Mo H, Parkin N, Pilot-Matias T, et al. 2015. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology. 62:1623–1632.
   PubMed Web of Science ®Google Scholar
• Luu L. 2015. Liver Transplants. Medscape. [accessed 2016 Mar 16]. http://emedicine.medscape.com/article/776313-overview.
   Google Scholar
• Malcolm BA, Liu R, Lahser F, Agrawal S, Belanger B, Butkiewicz N, Chase R, Gheyas F, Hart A, Hesk D, et al. 2006. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother. 50:1013–1020.
   PubMed Web of Science ®Google Scholar
• Matthew AN, Leidner F, Newton A, Petropoulos CJ, Huang W, Ali A, KurtYilmaz N, Schiffer CA. 2018. Molecular Mechanism of resistance in a clinically significant double-mutant variant of HCV NS3/4A protease. Structure. 26:1360–1372.
   PubMed Web of Science ®Google Scholar
• Matthew AN, Zephyr J, Hill CJ, Jahangir M, Newton A, Petropoulos CJ, Huang W, Kurt-Yilmaz N, Schiffer CA, Ali A. 2017. Hepatitis C virus NS3/4A protease inhibitors incorporating flexible P2 quinoxalines target drug resistant viral variants. J Med Chem. 60:5699–5716.
   PubMed Web of Science ®Google Scholar
• McCauley JA, McIntyre CJ, Rudd MT, Nguyen KT, Romano JJ, Butcher JW, Gilbert KF, Bush KJ, Holloway MK, Swestock J, et al. 2010. Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor. J Med Chem. 53:2443–2463.
   PubMed Web of Science ®Google Scholar
• McPhee F, Hernandez D, Yu F, Ueland J, Monikowski A, Carifa A, Falk P, Wang C, Fridell R, Eley T, et al. 2013. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology. 58:902–911.
   PubMed Web of Science ®Google Scholar
• McPhee F, Sheaffer AK, Friborg J, Hernandez D, Falk P, Zhai G, Levine S, Chaniewski S, Yu F, Barry D, et al. 2012. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother. 56:5387–5396.
   PubMed Web of Science ®Google Scholar
• Nalam MN, Ali A, Altman MD, Reddy GS, Chellappan S, Kairys V, Ozen A, Cao H, Gilson MK, Tidor B, et al. 2010. Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance. J Virol. 84:5368–5378.
   PubMed Web of Science ®Google Scholar
• Ozen A. 2013. Structure and dynamics of viral substrate recognition and drug resistance [Dissertation]. Worcester, MA: University of Massachusetts Medical School.
   Google Scholar
• Ozen A, Haliloğlu T, Schiffer CA. 2011. Dynamics of preferential substrate recognition in HIV-1 protease: redefining the substrate envelope. J Mol Biol. 410:726–744.
   PubMed Web of Science ®Google Scholar
• Ozen A, Sherman W, Schiffer CA. 2013. Improving the resistance profile of hepatitis C NS3/4A inhibitors: dynamic substrate envelope guided design. J Chem Theory Comput. 9:5693–5705.
   PubMed Web of Science ®Google Scholar
• Perni RB, Almquist SJ, Byrn RA, Chandorkar G, Chaturvedi PR, Courtney LF, Decker CJ, Dinehart K, Gates CA, Harbeson SL, et al. 2006. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother. 50:899–909.
   PubMed Web of Science ®Google Scholar
• Pockros PJ, Di Bisceglie AM, Bloom AB. 2014. Direct acting antivirals for the treatment of hepatitis C virus infection. Waltham, MA: UpToDate; [accessed 2018]. http://www.uptodate.com/contents/direct-acting-antivirals-for-the-treatment-of-hepatitis-c-virus-infection.
   Google Scholar
• Poordad F, Dieterich D. 2012. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat. 19:449–464.
   PubMed Web of Science ®Google Scholar
• Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, Heckaman M, Larsen L, Menon R, Koev G, et al. 2013. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 368:45–53.
   PubMed Web of Science ®Google Scholar
• Prabu-Jeyabalan M, Nalivaika E, Schiffer CA. 2002. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure. 10:369–381.
   PubMed Web of Science ®Google Scholar
• Romano KP, Ali A, Aydin C, Soumana D, Ozen A, Deveau LM, Silver C, Cao H, Newton A, Petropoulos CJ, et al. 2012. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog. 8:e1002832.
   PubMed Web of Science ®Google Scholar
• Romano KP, Ali A, Royer WE, Schiffer CA. 2010. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc Natl Acad Sci USA. 107:20986–20991.
   PubMed Web of Science ®Google Scholar
• Rosenquist A, Samuelsson B, Johansson PO, Cummings MD, Lenz O, Raboisson P, Simmen K, Vendeville S, de Kock H, Nilsson M, et al. 2014. Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor. J Med Chem. 57:1673–1693.
   PubMed Web of Science ®Google Scholar
• Rusere LN, Matthew AN, Lockbaum GJ, Jahangir M, Newton A, Petropoulos CJ, Huang W, Kurt Yilmaz N, Schiffer CA, Ali A. 2018. Quinoxaline-based linear HCV NS3/4A protease inhibitors exhibit potent activity against drug resistant variants. ACS Med Chem Lett. 9:691–696.
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta SK, Hussain M, Shah A, Cutler D, Zhang J, et al. 2007. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology. 132:1270–1278.
   PubMed Web of Science ®Google Scholar
• Schaefer EA, Chung RT. 2012. Anti-hepatitis C virus drugs in development. Gastroenterology. 142:1340–1350.
   PubMedGoogle Scholar
• Schrodinger, LLC. 2010 Aug. The PyMOL Molecular Graphics System, Version 1.3r1. https://pymol.org/2/support.html?#citing
   Google Scholar
• Schrodinger, LLC. 2015. Maestro, Version 10.2. https://www.schrodinger.com/citations
   Google Scholar
• Scola PM, Sun LQ, Wang AX, Chen J, Sin N, Venables BL, Sit SY, Chen Y, Cocuzza A, Bilder DM, et al. 2014. The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection. J Med Chem. 57:1730–1752.
   PubMed Web of Science ®Google Scholar
• Seiwert SD, Andrews SW, Jiang Y, Serebryany V, Tan H, Kossen K, Rajagopalan PT, Misialek S, Stevens SK, Stoycheva A, et al. 2008. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother. 52:4432–4441.
   PubMed Web of Science ®Google Scholar
• Sheng XC, Appleby T, Butler T, Cai R, Chen X, Cho A, Clarke MO, Cottell J, Delaney WEt, Doerffler E, et al. 2012. Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease. Bioorg Med Chem Lett. 22:2629–2634.
   PubMed Web of Science ®Google Scholar
• Silverman E. 2014. From riches to rags: vertex discontinues Incivek as sales evaporate. Wall Street J. 2014 Aug 12. http://blogs.wsj.com/pharmalot/2014/08/12/from-riches-to-rags-vertex-discontinues-incivek-as-sales-evaporate/.
   Google Scholar
• Sorbo MC, Cento V, Di Maio VC, Howe AYM, Garcia F, Perno CF, Ceccherini-Silberstein F. 2018. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018. Drug Resist Updat. 37:17–39.
   PubMed Web of Science ®Google Scholar
• Soumana D. 2015. Hepatitis C virus: structural insights into protease inhibitor efficacy and drug resistance. Worcester, MA: University of Massachusetts Medical School.
   Google Scholar
• Soumana DI, Ali A, Schiffer CA. 2014. Structural analysis of asunaprevir resistance in HCV NS3/4A protease. ACS Chem Biol. 9:2485–2490.
   PubMed Web of Science ®Google Scholar
• Soumana DI, Kurt Yilmaz N, Ali A, Prachanronarong KL, Schiffer CA. 2016. Molecular and dynamic mechanism underlying drug resistance in genotype 3 hepatitis C NS3/4A protease. J Am Chem Soc. 138:11850–11859.
   PubMed Web of Science ®Google Scholar
• Soumana DI, Kurt Yilmaz N, Prachanronarong KL, Aydin C, Ali A, Schiffer CA. 2016. Structural and thermodynamic effects of macrocyclization in HCV NS3/4A inhibitor MK-5172. ACS Chem Biol. 11:900–909.
   PubMed Web of Science ®Google Scholar
• Steinkuhler C, Biasiol G, Brunetti M, Urbani A, Koch U, Cortese R, Pessi A, De Francesco R. 1998. Product inhibition of the hepatitis C virus NS3 protease. Biochemistry. 37:8899–8905.
   PubMed Web of Science ®Google Scholar
• Summa V, Ludmerer SW, McCauley JA, Fandozzi C, Burlein C, Claudio G, Coleman PJ, Dimuzio JM, Ferrara M, Di Filippo M, et al. 2012. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother. 56:4161–4167.
   PubMed Web of Science ®Google Scholar
• Teresa Ng, Tami Pilot-Mati as, Liangjun Lu, Thomas Reisch, Tanya Dekhtyar, Preethi Krishnan, Jill Beyer, Rakesh Tripathi, Ron Pithawalla, Armen Asatryan, Andrew Campbell, Jens Kort, Christine Collins. 2014. A next generation HCV DAA combination: potent, pangenotypic inhibitors ABT-493 and ABT-530 with high barriers to resistance. 65th Annual Meeting of the American Association for the Study of Liver Diseases; Nov 7–11; Boston, MA.
   Google Scholar
• The MathWorks, Inc. 2014. MATLAB and toolboxes release 2014b. Natick, MA: The MathWorks, Inc.
   Google Scholar
• Tong X, Arasappan A, Bennett F, Chase R, Feld B, Guo Z, Hart A, Madison V, Malcolm B, Pichardo J, et al. 2010. Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease. Antimicrob Agents Chemother. 54:2365–2370.
   PubMed Web of Science ®Google Scholar
• Tong X, Bogen S, Chase R, Girijavallabhan V, Guo Z, Njoroge FG, Prongay A, Saksena A, Skelton A, Xia E, et al. 2008. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res. 77:177–185.
   PubMed Web of Science ®Google Scholar
• Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA. 2006. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res. 70:28–38.
   PubMed Web of Science ®Google Scholar
• Wang H, Geng L, Chen BZ, Ji M. 2014. Computational study on the molecular mechanisms of drug resistance of narlaprevir due to V36M, R155K, V36M + R155K, T54A, and A156T mutations of HCV NS3/4A protease. Biochem Cell Biol. 92:357–369.
   PubMedGoogle Scholar
• WHO. 2014. Hepatitis C Fact Sheet No. 164. [accessed 2014 Apr 23]. http://www.who.int/mediacentre/factsheets/fs164/enl.
   Google Scholar
• Xue W, Ban Y, Liu H, Yao X. 2014. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis. J Chem Inf Model. 54:621–633.
   PubMed Web of Science ®Google Scholar
• Xue W, Wang M, Jin X, Liu H, Yao X. 2012. Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3/4A: insights from molecular dynamics simulation, binding free energy calculation and network analysis. Mol Biosyst. 8:2753–2765.
   PubMed Web of Science ®Google Scholar
• Yao N, Reichert P, Taremi SS, Prosise WW, Weber PC. 1999. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure. 7:1353–1363.
   PubMed Web of Science ®Google Scholar